CJC-1295 and Ipamorelin are the most commonly paired peptides in growth hormone axis research, and the reason is simple: they press two different buttons. CJC-1295 acts at the GHRH receptor, Ipamorelin at the ghrelin receptor, and both of those feed into the same downstream event. Combining them is not doubling a dose, it is adding a second independent signal.

The pairing is written CJC 1295 Ipamorelin, CJC-1295 + Ipamorelin, CJC and Ipamorelin, CJC1295 Ipamorelin and Ipamorelin CJC 1295. This guide covers why the two go together, what each contributes, whether a blended vial or two separate vials makes more sense, where the pair sits in the GH axis, reconstitution volumes, and how to check a batch. PhaseOne supplies the blend in 10mg and 20mg vials, strictly for laboratory research.

On this page

Why they are combined | The two receptors | CJC-1295's half | Ipamorelin's half | Blend or separate vials | Where it sits in the GH axis | Reconstitution | Checking purity | FAQs

Key points at a glance

• CJC-1295 No DAC (CAS 863288-34-0) plus Ipamorelin (CAS 170851-70-4) in one vial
• Two separate receptors: GHRH receptor for CJC-1295, ghrelin receptor GHS-R for Ipamorelin
• Complementary rather than redundant, which is the whole reason the pairing exists
• The CJC-1295 in this blend is the No DAC form, with a half-life in hours rather than days
• Ipamorelin is studied for selectivity, meaning comparatively little cortisol or prolactin co-release
• Supplied as 10mg and 20mg vials, labelled by total peptide mass
• Both components are HPLC tested to at least 99% purity, certificate published publicly
• Research base is strong on each compound individually and thinner on the combination
• For laboratory research only

Why the two are combined

Growth hormone release from the pituitary is governed by more than one input. The GHRH receptor carries the releasing signal from the hypothalamus. The ghrelin receptor carries a separate signal that also drives release. Two doors into the same room.

CJC-1295 opens one, Ipamorelin opens the other. Because the receptors are distinct, the two compounds are not competing for the same binding site, and the research question becomes what happens when both inputs arrive together rather than what happens with more of one.

That is a genuinely different question from simply using a larger amount of a single compound, and it is why this pairing appears so consistently in the literature and in supplier catalogues alike.

The two receptors side by side

Full detail on each sits in the CJC-1295 guide and the Ipamorelin guide .

What CJC-1295 contributes

CJC-1295 is a 29 amino acid analogue of growth hormone releasing hormone, modified at four positions so the enzyme DPP-4 cannot break it down the way it destroys native GHRH within minutes. It binds the GHRH receptor on the anterior pituitary and amplifies a signal the body already sends.

The version in this blend is the No DAC form. DAC is a drug affinity complex that binds albumin and stretches the half-life out to days; without it, the window is measured in hours. That shorter window is precisely why the No DAC form is the one used in combination work, because it can be timed alongside a short-acting partner rather than sitting in the background for a week. The CJC-1295 guide sets out the No DAC and DAC difference in full.

What Ipamorelin contributes

Ipamorelin is a five amino acid peptide acting at the ghrelin receptor as a secretagogue. Its distinguishing research characteristic is selectivity: compared with older secretagogues such as GHRP-2 and GHRP-6, it is studied for driving growth hormone release with comparatively little effect on cortisol and prolactin.

That selectivity is the reason Ipamorelin became the standard partner for CJC-1295 rather than one of the older compounds. A cleaner signal makes the combination easier to interpret, because fewer confounding hormone changes come along with it.

One blended vial or two separate vials?

PhaseOne supplies both options, and the choice is a practical one rather than a mechanistic one.

If the research question is about the pair acting together, the blend is simpler and cheaper. If the question is what each receptor contributes on its own, separate CJC-1295 No DAC and Ipamorelin vials are the only way to vary them independently.

One thing to check on any blended vial, from any supplier: the vial is labelled by total peptide mass, so confirm the split between the two components on the certificate of analysis rather than assuming an even division.

Where the pair sits in the GH axis

The growth hormone axis runs in stages, and different research compounds act at different points along it. The CJC-1295 and Ipamorelin pairing sits at the top, on the receptors that trigger release.

Researchers mapping the whole pathway often work at more than one stage, since a change at the receptor level and a change at the IGF-1 level answer different questions. See the HGH 191AA guide , the IGF-1 LR3 guide and the growth hormone peptide guide .

Not the same kind of blend as GLOW or KLOW

PhaseOne sells other blends, and they are a different proposition. GLOW and KLOW combine compounds from separate research categories, pairing regenerative with cosmetic mechanisms that have little to do with one another.

This blend is the opposite case. Both components sit inside one pathway and act at two points within it, which makes the combination mechanistically coherent rather than simply convenient. Worth knowing, because the two kinds of blend should be read differently.

What the research does not establish

Each compound individually has a reasonably well characterised receptor mechanism. The combination is a weaker evidence base, and three limits are worth stating.

• The additive or synergistic claim is largely inferred from the mechanisms being separate rather than demonstrated head to head against each compound alone.
• Because the two are so often studied together, isolating what each contributed is hard, which is the main argument for buying separate vials.
• Findings on the DAC version of CJC-1295 are regularly quoted as if they applied to the No DAC form in this blend. They do not transfer.

Separate receptors making a combination plausible is not the same as a combination being proven better, and any supplier presenting it that way is going past the literature.

Reconstituting the blend

The blend arrives as a lyophilised powder and is reconstituted with bacteriostatic water . Concentrations below are total blend mass per millilitre, not per component. Units are on a 100 unit U-100 syringe.

2ml to 3ml in a 10mg vial is the common starting point, because at 1ml the draws are small enough that a single unit misread is a large proportional error. Work out any combination with the peptide dosage calculator , and see the reconstitution guide for technique.

Add the water slowly down the vial wall, swirl rather than shake, then refrigerate once dissolved and keep it out of light. The storage guide covers the stability variables in full.

Checking purity before you order

A blend certificate has to do more work than a single-peptide one. It needs to identify both components, not just report a single purity number, because a blend is the easiest place to under-supply one half and have nobody notice.

On an HPLC trace of this blend you should see two distinct peaks, one for each peptide. A single peak means one component is missing or the trace is not of the blend at all.

Every PhaseOne batch is independently tested to a standard of at least 99% purity by HPLC for both components, and the certificate is published in our public COA library . You can read it before ordering rather than taking a claim on trust. No COA is shipped with the vial; it is simply public.

For how to read a chromatogram, see the HPLC testing guide , and for what any supplier should be able to show you, the research standards guide .

Buying the blend in Australia

PhaseOne supplies the CJC-1295 No DAC and Ipamorelin blend in 10mg and 20mg vials from Australian stock, shipped Australia-wide, for laboratory research only.

Four checks against any Australian supplier of this pairing. Does the listing say No DAC explicitly, or just CJC-1295? Does the certificate identify both components rather than reporting one figure? Does it state the split between them? And is the stock held locally or drop-shipped from overseas, which affects transit time and the cold chain.

Researchers isolating each mechanism order CJC-1295 No DAC and Ipamorelin separately instead. Browse the full research range .

Related research guides

For each compound on its own, the CJC-1295 guide and the Ipamorelin guide . For the same receptor as CJC-1295, the Tesamorelin guide . For the rest of the axis, the HGH 191AA guide and IGF-1 LR3 guide . For the category, the growth hormone peptide guide . For handling, the reconstitution guide and storage guide . For verification, the HPLC testing guide and the COA library .

Frequently Asked Questions

Why are CJC-1295 and Ipamorelin used together?

Because they act at different receptors. CJC-1295 binds the GHRH receptor and Ipamorelin the ghrelin receptor, and both feed into growth hormone release. Combining them adds a second independent signal rather than more of the same one.

Do CJC-1295 and Ipamorelin work the same way?

No. One is a modified GHRH analogue acting at the GHRH receptor, the other a five amino acid secretagogue acting at the ghrelin receptor. They are not interchangeable and they are not redundant.

Is CJC-1295 Ipamorelin the same as CJC 1295 with Ipamorelin?

Yes. The pairing is written CJC 1295 Ipamorelin, CJC-1295 + Ipamorelin, CJC and Ipamorelin, CJC1295 Ipamorelin and Ipamorelin CJC 1295. They all describe the same two compounds.

Which version of CJC-1295 is in the blend?

The No DAC form. DAC is a drug affinity complex that binds albumin and extends the half-life to days; without it the window is hours, which is what allows it to be timed alongside a short-acting partner.

Should I buy the blend or two separate vials?

The blend if you are studying the pair as a unit, since it is cheaper and reconstitutes once. Separate vials if you need to vary one component without the other, which a fixed-ratio blend cannot do.

What vial sizes does the blend come in?

10mg and 20mg, labelled by total peptide mass across both components. Check the certificate for the split between them rather than assuming an even division.

How much bacteriostatic water should the blend be reconstituted with?

For a 10mg vial, 2ml to 3ml is the usual starting point, giving 5mg/ml or 3.3mg/ml of total blend. The table above lists the options for both vial sizes and converts each to syringe units.

Why is Ipamorelin the usual partner rather than GHRP-2 or GHRP-6?

Selectivity. Ipamorelin is studied for driving growth hormone release with comparatively little cortisol or prolactin co-release, which makes the combination easier to interpret than one built on a less selective secretagogue.

Is this blend the same kind of product as GLOW or KLOW?

No. GLOW and KLOW combine compounds from different research categories. This blend combines two compounds inside a single pathway, acting at two points within it, which makes it mechanistically coherent rather than just convenient.

How does the blend relate to HGH 191AA?

The blend acts upstream, on the receptors that trigger growth hormone release. HGH 191AA is growth hormone itself. One works on the signal, the other supplies the hormone.

How does the blend relate to IGF-1 LR3?

IGF-1 LR3 sits further downstream again, as an analogue of the mediator that carries out many of growth hormone's effects. Three different stages of the same axis.

Is the combination proven better than either compound alone?

No. The rationale is mechanistic, resting on the receptors being separate, and head to head comparisons against each compound alone are limited. Plausible is not the same as demonstrated.

How should the blend be stored?

Lyophilised vials refrigerated and out of light. Once reconstituted, refrigerate immediately, keep it dark, and prepare only what the work needs.

How is a blend's purity verified?

By HPLC, which should show two distinct peaks, one for each peptide. A single peak means one component is missing. The certificate should identify both components rather than quoting one purity figure.

What purity is the PhaseOne blend?

At least 99% by independent HPLC testing for both components, with the certificate for each batch published in our public COA library.

Does a COA come with the vial?

No. Certificates are not shipped with orders. Every batch certificate is published in our public COA library instead, so anyone can check a result before buying.

Is this blend approved in Australia?

No. Neither component is registered on the ARTG or approved for supply as a medicine, so no pharmacy or chemist stocks it. It is supplied through research suppliers for laboratory research only.

Where can I buy a CJC-1295 and Ipamorelin blend in Australia?

PhaseOne supplies it in 10mg and 20mg vials from Australian stock, shipped Australia-wide, for laboratory research only, with batch-specific HPLC certificates published publicly.

Disclaimer

All products supplied by PhaseOne are intended strictly for laboratory research purposes only. Products are not intended for human consumption, therapeutic use, cosmetic use, veterinary use, or diagnostic applications.